TABLE 2.
The comparison of characteristics between G3+ RILTs group and non G3+ RILTs group (n = 85)
| Variable | RILTs (grade ≥3) (n = 17) | RILTs (grade <3) (n = 68) | p‐value | |
|---|---|---|---|---|
| Sex | Male/Female | 17/0 | 63/5 | 0.249 |
| Age (y) | Median (range) | 65 (54–78) | 68 (46–82) | 0.347 |
| Performance status | 1 vs. 2 | 8/9 | 23/45 | 0.311 |
| Smoking status | Never vs. current or former smoker | 2/15 | 13/55 | 0.477 |
| Clinical stage | IIIA vs. IIIB | 5/12 | 28/40 | 0.373 |
| Tumor location | Lower lobe vs. non‐lower lobe | 7/10 | 24/44 | 0.652 |
| Histology | Squamous vs. non‐squamous | 9/8 | 45/23 | 0.599 |
| Treatment | cCRT vs. sequential CRT or RT alone | 6/11 | 11/57 | 0.078 |
| Radiation dose | Median (range) | 60.00 (40.00–66.00) | 60.00 (40.00–70.00) | 0.771 |
| %FVC (n = 73) | Median (range) | 70.10 (59.80–107.30) | 68.60 (41.00–125.30) | 0.178 |
| MLD (Gy) (n = 83) | Median (range) | 13.71 (2.44–16.63) | 13.36 (2.31–20.69) | 0.179 |
| V5% (n = 83) | Median (range) | 59.65 (29.39–86.54) | 51.27 (16.61–84.76) | 0.148 |
| V20% (n = 83) | Median (range) | 24.43 (12.99–28.60) | 21.55 (8.77–30.39) | 0.107 |
| Honeycombing score on CT | 0–1 vs. 2–3 | 6/11 | 48/20 | 0.010 |
| mGAP score (n = 73) | >3 vs. ≤3 | 3/9 | 25/36 | 0.298 |
Note: The data are reported as the number or median (range). The p‐value was calculated by comparing patients with and without G3+ RILTs.
Abbreviations: RILTs, radiation‐induced lung toxicities; cCRT, concurrent chemoradiotherapy; CRT, chemoradiotherapy; RT, radiotherapy; mGAP, modified age gender, and pulmonary physiology index; FVC, forced vital capacity; MLD, mean lung dose; V5, the percentage of lung volume minus gross tumor volume receiving >5 Gy; V20, the percentage of lung volume minus gross tumor volume receiving >20 Gy.